Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mattersburg – page 4

55 clinical trials in Mattersburg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mattersburg at a glance
55
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

55 trials in Mattersburg

Open in trial search

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Oncology Inc.

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Betula Pollen Extract
  • Sponsor:Stallergenes

Neoplasm

Not recruiting

Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Takeda Development Center Americas Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mattersburg

What the registry says about research in the country

01 Cardiovascular Diseases

In Mattersburg, clinical trial activity in cardiovascular diseases is focused on reducing the risk of serious heart complications and improving long-term outcomes for people with atherosclerotic cardiovascular disease.

  • Studies in atherosclerotic cardiovascular disease and broader cardiovascular disease
  • Research on preventing major heart events and related complications
  • Work aimed at improving treatment effectiveness for high-risk patients

These trials are helping assess whether new therapies can better protect patients from heart attacks, cardiovascular death, and other major events.

02 Nutritional and Metabolic Diseases

Clinical research in nutritional and metabolic diseases in this Austrian city is closely linked to obesity, overweight, and related metabolic risk factors that can affect heart and kidney health.

  • Trials involving obesity and overweight
  • Studies connecting weight-related conditions with cardiovascular disease
  • Research evaluating new approaches to improve metabolic health

The main goal is to understand whether emerging treatments can lower long-term disease burden and support better prevention.

03 Cardiovascular Risk Reduction

Several trials are examining whether investigational therapies can reduce the chance of first or repeat major cardiovascular events in participants with elevated risk factors.

  • Atherosclerotic Cardiovascular Disease and event prevention
  • Elevated Lp(a) as a key risk factor under study
  • Testing new options to reduce heart-related morbidity and mortality

This research focuses on whether better risk control can help prevent heart attacks, urgent procedures, and other serious outcomes.

04 Kidney and Cardiometabolic Health

Some studies also look beyond the heart, examining whether treatments can help preserve kidney function in people with overlapping cardiometabolic conditions.

  • Chronic Kidney Disease in combination with heart risk
  • People living with obesity and related complications
  • Trials exploring whether therapy can support both heart and kidney outcomes

These projects aim to find approaches that address multiple health concerns at once, which is especially important for patients with complex chronic disease.

05 Lipoprotein(a) Research

A notable area of investigation is Lipoprotein(a), or Lp(a), where researchers are testing whether lowering this inherited risk marker can reduce cardiovascular events.

  • Elevated Lp(a) and first major cardiovascular events
  • Studies focused on preventing coronary heart disease and myocardial infarction
  • Evaluating new strategies for people at heightened genetic risk

This work could improve prevention for patients whose heart risk remains high despite standard care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.